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Disease that Includes Low-Dose Methotrexate Is
Associated with a High Response Rate
Yu Wang, Lan-ping Xu, Dai-hong Liu, Huan Chen, Yu-hong Chen, Wei Han,
Kai-yan Liu, Xiao-Jun HuangWe report the results of low-dose methotrexate (MTX) as first-line therapy mostly in combination with
other immunosuppressive agents in patients with chronic graft-versus-host disease (cGVHD) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Between November 2001 and March 2008, 86 patients
with cGVHD after allo-HSCTreceived low-dose MTX therapy until a complete or partial response (CR, PR)
was achieved, or until treatment failure or intolerable side effects were found. The median time from HSCT
to the start of MTXwas 154 (range: 80-993) days. The median number of MTX administrations was 4 (range:
2-18). The overall response rate among all enrolled patients was 83% (71 of 86 patients). The response rate
for GVHD involving various organs was 90% (45 of 50) in the skin, 75% (39 of 52) in the liver, 42% (5 of 12) in
the mouth, 3 of 7 in the eye, and 2 of 2 in the gut. In addition, MTX treatment allowed for a significant re-
duction in the prednisone dosage (median 90%) from 20 (2.5-100) mg at the start of MTX administration to 5
(0-30) mg 1 month after MTX was last used. Multivariate analysis showed that the only significant factor re-
lated to higher CR rate was sole organ involvement (P5.007). Grade 3 toxicities occurred in only 3 patients
presenting cytopenias or oral mucositis. From this analysis, MTX appears to be awell-tolerated, effective, and
inexpensive agent when used as a first-line treatment in combination with other immunosuppressive agents
for cGVHD, especially for skin or sole organ involvement without concomitant thrombocytopenia.
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host diseaseINTRODUCTION
Chronic graft-versus-host disease (cGVHD) oc-
curs in up to 60% of patients with HLA-identical
sibling donors and in 70% of those with unrelated or
an HLA-mismatched related donor after allogeneic
hematopoietic stem cell transplantation (allo-HSCT)
[1-3]. Some patients fail conventional immunosup-
pressive therapy and succumb to depression of their
immune system from GVHD and secondary infection
[4,5].
Methotrexate (MTX) has been widely used as an
anti-inflammatory and immunomodulatory agent for
the treatment of patients with rheumatoid arthritiseking University People’s hospital, Institute of Hematol-
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(7.5-25 mg) administration, and its efficacy and safety
have been documented in the literature [6-10]. In addi-
tion, low-doseMTXhas been employed for a long time
as part of the prophylaxis for acute GVHD (aGVHD)
after HSCT [11-14]. On the other hand, MTX has
also been used as a part of a combined regimen for
the treatment of aGVHDand cGVHD; however, there
were a few published reports, most including \40
patients and only as salvage therapy, to evaluate the fea-
sibility of MTX treatment for cGVHD [15-17]. In our
own previous report, MTX was used to treat 19
aGVHD and 21 cGVHD patients predominantly as
salvage therapy with encouraging results [18].
Early initiation of drug therapy may be more effec-
tive than salvage therapy for the treatment of cGVHD.
Furthermore, patients with cGVHDmay benefit from
early administration of MTX to lower the incidence of
infectious complications and mortality related to the
patients’ underlying immunocompromised state, as
well as to the previous immunosuppressive agents, by
shortening the period of immunosuppression. To
date, there have been no other published reports eval-
uating the potential efficacy that this drug might have505
Table 1. Patient Characteristics
Characteristic n
Total patients 86
Age (median) 30 (range: 8-50)
Sex (male:female) 53:33
506 Biol Blood Marrow Transplant 15:505-511, 2009Y. Wang et al.for treating cGVHD at an earlier stage of disease.
Since 2001, we have employed low-dose MTX treat-
ment for cGVHD. In this report, we show the data
from 86 patients receiving low-dose MTX as a first
line treatment for cGVHD.Onset of GVHD (median) (day) 153 (range: 80-993)
Disease
Acute myelogenous leukemia 24
Acute lymphoid leukemia 27
Chronic myelogenous leukemia 28
Myelodysplastic syndrome 5
Aplastic anemia 1
Multiple myeloma 1
Donor and HLA histocompatibility
Related 6 of 6 identical 39
Mismatched related 43
Unrelated 6 of 6 identical 1
Mismatched unrelated 3
Stem cell source
Bone marrow + peripheral blood cell 54
Peripheral blood cell 32
Preparative regimen
Bu/Cy or Cy/TBI 38
Bu/Cy or Cy/TBI plus ATG 46
Cy/ATG 2
Onset of chronic graft-versus-host disease (cGVHD)
De novo 44
Quiescent 36
Progressive 6
Type of cGVHD
Limited 38
Extensive 48
Site of GVHD
Skin 50
Liver 52
Mouth 12
Eye 7
Gut 2
Time to MTX start (days) median (range)
From allo-HSCT 154 (80-993)PATIENTS AND METHODS
Patients
The study was approved by the institutional review
board of the Peking University Institute of Hematol-
ogy. All patients gave written informed consent before
participating in the study. Between November 2001
and March 2008, 86 consecutive patients with
cGVHD given oral or parenteral low-dose MTX (10
or 15 mg, respectively) treatment as a first-line therapy
were enrolled in this series. Data from 17 of these 86
patients were previously reported in 2005 [18], and
these patients were further followed up in this study.
In all cases, MTX was used as a first line therapy
with or without other concomitant immunosuppres-
sive treatments. Patients receiving MTX as a salvage
therapy (where additional immunosuppressive agents
other than MTX were given before MTX administra-
tion for treatment of newly diagnosed cGVHD) were
not included in this series. Patients were informed
about the risks, benefits, and uncertain outcomes
associated with the use of MTX, and alternatives
were explained. Characteristics of the 86 patients
were summarized in Table 1.From the day of diagnosis of GVHD 1 (1-25)
Follow-up from onset of cGVHD (d) median (range) 402 (36-2164)
Follow-up from HSCT (days) median (range) 575 (146-2309)
Immunosuppressive agents before MTX
administration
CsA (50-200 mg orally in divided doses daily) 38
CsA + prednisone (2.5-75 mg daily) 25
Prednisone (2.5-15 mg daily) 2
CsA + prednisone + MMF 10
CsA + MMF 5
None 6Transplant Procedure
Details of the patients, conditioning regimen, in-
fused cell counts, GVHD prophylaxis regimen, and
supportive care measures were described in the previ-
ous study [18]. Patient-donor relationship and stem
cell source are shown in Table 1.Bu indicates busulfan; Cy, cyclophosphamide; TBI, total- body irradiation;
ATG, antihuman thymocyte immunoglobulin; GVHD, graft-versus-host
disease;MTX,methotrexate;CsA, cyclosporineA;MMF,mycophenolate
mofetil.Diagnosis and Grading of cGVHD
Prior to initiation of the treatment, patients under-
went a thorough evaluation to ascertain the severity
and extent of GVHD, including physical examination,
laboratory evaluation, and consultation without tissue
biopsy results. cGVHD was classified into several cat-
egories including: limited (localized skin involvement
only or mildly increased transaminase level only) and
extensive cGVHD (generalized skin, liver involvement
with hyperbilirubinemia, multiple organ cGVHD) in
accordance with the extent of the disease [19]; progres-
sive cGVHD, whether it followed as a direct extension
from aGVHD; quiescent cGVHD, if prior aGVHD
had completely resolved; and de novo cGVHD, if
there was no prior aGVHD at all. Onset forms and
types of cGVHD among the 86 patients are describedin Table 1. The most frequently involved organs were
the skin and liver.Involved Organ of cGVHD
Fifty patients had skin involvement manifesting as
lichenoid papules (other skin manifestations such as
sclerosis, lichen-sclerosis like, poikiloderma, or depig-
mentation were not encompassed in this group be-
cause of their long-standing and refractory nature),
52 with liver involvement had an elevation of enzymes
(3 accompanied by an elevated bilirubin), 12 with oral
Biol Blood Marrow Transplant 15:505-511, 2009 507MTX for Chronic GVHDinvolvement, 7 with eye involvement, and 5 patients
presented with grade 2 or 3 thrombocytopenia.
Immunosuppressive Agents before Treatment
with MTX
Details of immunosuppressive agents before treat-
ment with MTX are described in Table 1.
Protocol of MTX Therapy
MTX was given i.v. at a dose of 10 mg or orally at
a dose of 15 mg, repeated at day 3 or 4 and day 8 after
the first dose and then at a weekly interval, until the pa-
tients showed a complete or partial response, treat-
ment failure or intolerable side effects.
i.v. MTX was used in all in-patients and patients
with gut GVHD because of concern that absorption
might be limited by severe gut GVHD. Otherwise, it
was determined at each physician’s discretion. Drug
dosage was adjusted according to the hemogram.
MTX was administered at a dose of 5 mg i.v. or 10
mg orally if WBC \2  109/L or platelet \50 
109/L. Leukovorin was not administered to all pa-
tients. Patients were scheduled to receive 3 doses
(numbers of MTX administrations) for evaluation of
the efficacy. If patients had improvement after 3 doses
and were able to tolerate the toxicity, additional doses
were given at each physician’s discretion. In patients
who had no response (progression or stable disease) af-
ter 3 doses, MTX administration was stopped and
treatment was switched to other immunosuppressive
agents.
For limited cGVHD, MTX was given with the
original immunosuppressive regimen unchanged.
Prednisone, cyclosporine A (CsA), and other immuno-
suppressive agents were gradually tapered off if
cGVHD could be controlled with the sole addition
of MTX. For extensive cGVHD, additional immuno-
suppressive agents other than the original ones can be
administered in combination with MTX, which was
determined by the severity and response after the ini-
tial 2 MTX doses. If patients who obtained a response
flared up at least 2 weeks from the last dose of MTX,
MTX can be given for retreatment with the original
immunosuppressive regimen unchanged.
Evaluation of Response and Toxicity
Patients were evaluated 3 times per week after
therapy. A complete response (CR) was classified as
complete disappearance of all clinical manifestations
of cGVHD. A partial response (PR) was defined as
a change from extensive to limited stage or a more
than 50% improvement in objective parameters of
cGVHD manifestations including surface area of skin
involvement, transaminase, or bilirubin level. A re-
sponse in oral cGVHD was more difficult to quantitate
objectively, but required symptomatic improvement aswell as physician assessment of comparative improve-
ment. Overall response (OR) included CR and PR.
Patients were considered to have no response (NR)
or treatment failure if GVHD progressed or failed to
improve (stable disease) after 3 administrations of
MTX. When there was no change in the extent or
severity of the disease it was considered to be stable
disease (SD), and in the event of worsening of the
above-mentioned parameters it was termed progres-
sive disease (PD). The common terminology criteria
(CTC) for adverse events version 3.0 was used to grade
the severity of side effects.
Statistical Methods
Data were collected on case report forms by med-
ical record review. Laboratory values (complete blood
counts, liver function tests, and renal function tests)
were analyzed in reference to normal range and pre-
treatment baseline. The time elapsed between the on-
set of cGVHD and HSCT was defined as the time
from HSCT to the onset of any grade of cGVHD.
For comparison of group characteristics, Pearson
chi-square test was applied for univariate analysis,
and stepwise logistic regression was used for multivar-
iate analysis. The probability of survival, the time
course for cGVHD response, and subsequent recur-
rence were estimated using the method of Kaplan
and Meier. The surviving patients were followed up,
and the results of the follow-up examinations were an-
alyzed on August 1, 2008. Unless otherwise specified,
all the reported P values were based on 2-sided hypoth-
esis tests. The SPSS software packages were used for
data analyses.RESULTS
Drug Use
MTX was started at a median of 154 days (range:
80-993) after HSCT as first-line therapy with or with-
out other concomitant immunosuppressive agents for
treatment of cGVHD, which occurred at a median of
153 days (range: 80-993 days) after HSCT in 86 pa-
tients (Table 1). The drug was administered orally or
intravenously in 25 and 61 patients, respectively.
Fifty-four patients started MTX therapy with original
immunosuppressive regimen unchanged including
3 patients receiving MTX alone with no original
immunosuppressive agents, and additional immuno-
suppressive was given in combination with MTX in
32 patients with extensive cGVHD.
Responses
All 86 patients except 1 received at least 3 doses of
MTX as scheduled. Only 1 patient received 2 doses of
MTX because of severe cytopenia; however, the
Table 2. The Usage of MTX in PatientsWho Had a Response
Number of doses or cumulative dose in mg Median (range)
Doses to show improvement (<50% improvement,
not reaching PR)
2 (1-3)
Doses to achieve maximal response (CR or PR) 4 (1-10)
cumulative dose to achieve a CR or PR 35 (10-100)
Additional doses after the initial three doses 2 (1-15)
cumulative dose of additional administrations 20 (5-120)
Total number of doses of MTX administration 4 (2-18)
Total cumulative dose 40 (15-165)
CR indicates complete response; PR, partial response; MTX, metho-
trexate.
Figure 1. Cumulative overall response rate after MTX therapy.
Seventy-one of 86 patients achieved overall response with a median of
4 (1-10) MTX administrations.
508 Biol Blood Marrow Transplant 15:505-511, 2009Y. Wang et al.patient achieved CR after 2 doses of MTX. Therefore,
all patients were eligible for efficacy and safety evalua-
tion.
TheOR and CR rates were 83% (71 of 86 patients)
and 62% (53 of 86, respectively). MTX usage and im-
munosuppression taper results are shown in Table 2
and Table 3. The time course for cGVHD response
is shown in Figure 1.
Among the 71 patients who obtained a response,
25 (35.2%) flared up after a median of 50 days (range:
15-602 days) from the last MTX. Twenty-one of the
25 patients were given MTX again and 17 got
a response with 12 CR and 5 PR. The other 46 of 71
patients who obtained a response after MTX adminis-
tration did not flare up after a median of 339 days
(range: 25-1851 days) from the end of the therapy.
The time course for cGVHD recurrence was shown
in Figure 2.
Subset analysis of responses was shown in Table 4.
Overall response rates R and CR rates for skin involve-
ment were significantly higher (80% and 90%) than
those of other involved organs (P\ .01); CR rate for
single organ involvement was significantly higher
than those for nonsingle ones: 71% versus 38%, P 5
.006; when accompanied by an elevated bilirubin or
grade 2 thromocytopenia, CR rates were significantlyTable 3. Immunosuppression Taper 1 Month after MTX Last
Used
Other immunosuppressive agents tapering
Patient number and
percentage
Initial prednisone dose median (range) 43 patients*
20 (2.5-100) mg
Prednisone dose 1 month after MTX therapy 23 patients discontinued
median (range) 0 (0-25) mg
Percent of prednisone dose reduction 100 (2.5-100)%
Sole tapering of CsA 38 patients
Sole tapering of prednisone 32 patients
Sole tapering of MMF 3 patients
Simultaneous tapering of prednisone and MMF 6 patients
Simultaneous tapering of CsA, prednisone and
MMF
4 patients
Simultaneous tapering of CsA and prednisone 1 patient
MTX indicates methotrexate; CsA, cyclosporine A; MMF, mycopheno-
late mofetil.
*Prednisone was used in 43 patients either as a regularly reduced orig-
inal use or as a concomitant additional use with MTX.lower than those without the factor: 0 of 3 versus
64%, P5 .025 and 1 of 5 versus 64%, P5 .049, respec-
tively. R and CR rates in patients receiving MTX,
in combination with additional immunosuppressive
agents or receiving MTX on original immunosup-
pressive agents, including the 3 patients receiving
MTX alone with no original immunosuppressive
agents were: 88% versus 80% (P 5 .40) and 69%
versus 57% (P 5 .36), respectively.Factors Influencing CR Rate
In multivariate analysis, the following variables
were considered as covariates: sole organ involvement
or not, patient age, with or without concomitant
thrombocytopenia, progressive onset or not, and
MTX in combination with other immunosuppressiveFigure 2. Cumulative cGVHD recurrence after MTX discontinued.
Among the 71 patients who obtained a response, 25 flared up after a
median of 50 days (range: 15-602 days) from the last MTX.
Table 4. Univariate Analysis of Overall Responses and
Complete Responses
Variable
Patients
(n)
CR,
n (%) P*
OR,
n (%) P*
Onset forms of cGVHD .21† .01†
Quiescent 44 26 (59%) 31 (71%)
De novo 36 25 (69%) 34 (94%)
Progressive 6 2/6 6/6
Types of cGVHD .48 .72
Limited 38 25 (66%) 32 (84%)
Extensive 48 28 (53%) 39 (82%)
Involved organ <.01‡ <.01‡
Skin 50 40 (80%) 45(90%)
Liver 52 27 (52%) 39 (75%)
Mouth 12 4 (33%) 5 (42%)
Eye 7 3 (29%) 3 (29%)
Gut 2 2/2 2/2
Number of involved organs .006 .11
Sole organ 62 44 (71%) 54 (87%)
Multiorgans 24 9 (38%) 17 (71%)
$Grade 2 thrombocytopenia .049 .58
With 5 1/5 5/5
Without 81 52 (64%) 66 (82%)
Elevated bilirubin .025 .44
With 3 0/3 2/3
Without 83 53 (64%) 69 (83%)
Treatment regimen .37† .06†
MTX + original IS 51 30 (59%) 42 (82%)
MTX + additional IS 32 22 (69%) 28 (88%)
MTX alone 3 1/3 1/3
Detailed combinations .39‡ .22‡
CsA + MTX 26 19 (73%) 22 (85%)
CsA + pred + MTX 35 18 (51%) 27 (77%)
CsA + pred + MMF + MTX 19 13 (68%) 18 (95%)
CsA + MMF + MTX 3 2/3 3/3
MTX alone 3 1/3 1/3
MTX administration manner .093 .21
Orally 25 19 (76%) 23 (92%)
Intravenously 61 34 (56%) 48 (79%)
Total 86 53 (62%) 71 (83%)
CR indicates complete response; OR, overall response; IS, immunosup-
pressive agents; pred: prednisone; MTX, methotrexate; CsA, cyclospor-
ine A; MMF, mycophenolate mofetil.
*For comparison of CR and OR rates within different variables, chi-
square test was applied for univariate analysis.
†Two degrees of freedom test.
‡Fur degrees of freedom test.
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factor related to higher CR rate was sole organ in-
volvement (P 5 .007).Toxicity
CTC grade 2 and 3 cytopenia occurred in 3 and 2
patients. Two patients developed grade 3 thrombocy-
topenia and/or leukopenia after 2 and 8 doses with dos-
age of 20 and 40 mg, respectively. The platelet counts
of these 2 patients were from 51  109/L to 36  109/
L and from 74 109/L to 45 109/L from the start to
the end of MTX administration, respectively. Neither
of the patients required blood product transfusion or
treatment with hematopoietic growth factors. One pa-
tient discontinued themedication after 2 doses because
of cytopenia. No patient was withdrawn from the study
because of hematologic side effects. Hematologictoxicity among patients receiving MTX in combina-
tion with additional immunosuppressive agents,
remaining on the original immunosuppressive agents
or receiving MTX alone was 9.4%, 3.9% and 0 of 3,
respectively.
Seven patients aggravated from normal to grade 1,
2, or 3 oral mucositis after a median of 3 doses (range:
3-5 doses) and a median dose of 30 mg (range: 30-50
doses). Other nonhematologic toxicity or therapy-
related infection or hemorrhage was not observed.
Long-Time Follow-up and Survival
Up to August 1, 2008, with a median follow-up of
402 days (range: 36-2164 days) from onset of cGVHD
and 575 days (range: 146-2309 days) from HSCT, 10
patients relapsed of leukemia; among whom 4 died
from leukemia relapse, 4 achieved complete remission
after chemotherapy and donor lymphocyte infusion
(DLI), 1 achieved complete remission after second
transplantation, and another 1 remained alive with leu-
kemia relapse status. In all, 8 patients died from inter-
stitial pneumonia (n 5 4) or leukemia relapse (n 5 4),
78 patients remained alive and 77 remained disease-
free, with a median survival of 424 days (range: 36-
2164) from onset of cGVHD and 608 days (range:
146-2309) from HSCT. Mortality among patients
receivingMTX in combination with additional immu-
nosuppressive agents, receiving MTX alone or re-
maining on the original immunosuppressive regimen
was 15.6%, 0 of 3, and 5.6% (P 5 .28), respectively.
Estimated survival at 1 and 1.5 years were 96% and
90%. There was a difference in the estimated survival
at 1.5 years between patients receivingMTX in combi-
nation with additional immunosuppressive agents and
patients receiving MTX on the original immunosup-
pressive regimen including the 3 patients receiving
MTX alone with no original immunosuppressive
agents: 80 and 96%, (P 5 .053).DISCUSSION
Recent studies have suggested that a low dose of
MTX, in addition to having antimitotic effects, can
induce a sustained suppression of T cell activation,
supporting its use in GVHD therapy [20]. Previous
to this report, there were no other published reports
that evaluated the potential efficacy that this drug
might have for treatment of cGVHD as a first-line
therapy. The current study was initiated to evaluate
the safety and both the efficacy of MTX as a first-
line treatment for cGVHD in a larger population
and the factors influencing the response rate of MTX.
Early initiation of drug therapy may be more effec-
tive for the treatment of cGVHD. Vogelsang et al [21]
reported that 7 of 21 patients with poor risk features
had a CR using thalidomide as part of the first-line
510 Biol Blood Marrow Transplant 15:505-511, 2009Y. Wang et al.therapy in combination with prednisone (PSE)/CsA,
whereas Parker et al [22] found that patients receiving
thalidomide as a salvage treatment had a CR rate of
20%. Gaziev et al [23] found that patients receiving
a 3-drug regimen with CsA, methylprednisolone
(MP), and azathioprine (AZ) as first-line therapy had
higherCR rates and fewer complications than did those
receiving this combination as a salvage treatment.
To our knowledge, there have been 4 published re-
ports to evaluate the feasibility of MTX in the treat-
ment of cGVHD as a salvage therapy, using a variety
of assessments and definitions of responses [15-18].
Response rates were reported to be 55% to 76% for
cGVHD including 8-21 patients. Giaccone et al [15]
reported with a median of 38 months after the diagno-
sis of cGVHD, 14 patients began low-dose MTX at
a median dose of 10 mg weekly for a median of 25
weeks, where 5 of 9 closely watched patients experi-
enced improvement or resolution of GVHD. Inagaki
et al [16] reported a response rate of 58.8% with
MTX at a dose of 10 mg/m2 weekly for a median of
18 months for the treatment of cGVHD in children.
de Lavallade et al [17] found that 6 of 8 patients receiv-
ingMTX at a dose of 5mg/m2 weekly for amedian of 4
infusions as a salvage treatment had a response. These
reports demonstrated the possible steroid-sparing ef-
fect of low-dose MTX for patients with long-standing
cGVHD; however, it remained difficult to judge the
potential efficacy that this drug might have for treat-
ment of cGVHD at an earlier stage of the disease. In
Inagaki et al’s report, CR was achieved in 4 of 17
patients with cGVHD [16]. In these 4 CR patients, 3
began low-dose MTX soon after the diagnosis of
cGVHD and the remaining patient began 25 days after
the diagnosis. Our earlier study included a small num-
ber of successful cases withMTX as a first-line therapy
for the treatment of cGVHD and achieved a response
rate of 76% for cGVHD patients [18]. Our present
study supports and confirms that larger scale use of
MTX as a first-line therapy had better outcomes
than when used as a salvage therapy.
It should be emphasized that most patients given
MTX did receive other immunosuppressive agents
such as CsA and MP (or prednisone), and the response
rate might be increased when MTX is given in combi-
nation with other agents. Compared with patients
receiving MTX in combination with other immuno-
suppressive agents, patients receiving MTX alone
had a lower response rate. One prospective cohort
study demonstrated that the response rate to combina-
tion therapy with steroid, CsA, and AZ was 61% [24].
Gaziev et al [23] used CsA, MP, and AZ as first-line
therapy with a CR rate of 94%. Notably, that study
population was small (18 patients) and young (median
age of 11 years). In our present study, high response
rates and minimal toxicity was demonstrated and
most of the patients were able to either discontinueor reduce other immunosuppressive agents such as
CsA, MP, or mycophenolate mofetil (MMF), which
may be beneficial in the recovery of immune function.
Randomized trials of comparing this regimen with
other multidrug therapy for newly diagnosed cGVHD
are needed to confirm its superiority.
The results were particularly good for patients
with skin involvement. In fact, many othermedications
or complications after HSCT might influence the res-
olution process of liver disease. These results were in
accordance with Inagaki et al’s report [16]. GVHD-re-
lated symptoms inmost patients improved within a few
days and were controlled within 2-3 weeks after initia-
tion of MTX. MTX was also effective on recurrent
GVHD, which had previously responded to MTX.
Severe cytopenia seemed less than that of previous
reports [15-17], maybe because of lower dose, shorter
period ofMTXadministration, andMTXgiven beyond
day 100 after transplantation in this series.Nevertheless,
close monitoring of blood cells counts is necessary
whenever MTX is administered. There were no epi-
sodes of severe infectious complications obviously
related to MTX. No other well-described adverse
events, such as gastrointestinal symptoms, immune-
mediated pneumonitis, or renal impairment were seen
even in the patients with long-term follow up. Low-
dose use of MTX contributed to its safety. Therefore,
these results confirmed that low-dose MTX might be
safe and well tolerated in the larger population.
In summary, our results demonstrate that MTX ap-
pears to be a well-tolerated, effective, and inexpensive
agent as a frontline therapy in combination with other
immunosuppressive agents for treatment of cGVHD,
especially for skin or sole organ involvement without
concomitant thrombocytopenia. Aprospective random-
ized trial is required to confirm the potential efficacy.ACKNOWLEDGMENTS
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